{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:37:15Z","timestamp":1792496235666,"version":"4.5.0"},"reference-count":181,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,2]]},"DOI":"10.20945\/2359-4292-2024-0422","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T12:16:42Z","timestamp":1733228202000},"source":"Crossref","is-referenced-by-count":11,"title":["Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)"],"prefix":"10.20945","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1561-2926","authenticated-orcid":false,"given":"Rodrigo O.","family":"Moreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2292-1735","authenticated-orcid":false,"given":"Cynthia M.","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-5837","authenticated-orcid":false,"given":"Alexandre","family":"Hohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7213-2418","authenticated-orcid":false,"given":"Cristiane","family":"Moulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6721-6437","authenticated-orcid":false,"given":"F\u00e1bio","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1987-8348","authenticated-orcid":false,"given":"F\u00e1bio R.","family":"Trujilho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5873-9498","authenticated-orcid":false,"given":"Fernando","family":"Gerchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4656-4381","authenticated-orcid":false,"given":"Livia L.","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1278-0406","authenticated-orcid":false,"given":"Marcio C.","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-7532","authenticated-orcid":false,"given":"Maria Edna","family":"Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7432-9085","authenticated-orcid":false,"given":"Rodrigo N.","family":"Lamounier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5592-1603","authenticated-orcid":false,"given":"Simone","family":"van de Sande-Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-1905","authenticated-orcid":false,"given":"Tha\u00edsa D. G.","family":"Trujilho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5433-3386","authenticated-orcid":false,"given":"Paulo A. C.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-5065","authenticated-orcid":false,"given":"Bruno","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"key":"key20241203121637_B1","author":"World Obesity Federation","unstructured":"1. World Obesity Federation. World Obesity Atlas 2023. Available from: https:\/\/data.worldobesity.org\/publications\/?cat=19. Accessed on: Jun 2024.","journal-title":"World Obesity Atlas 2023"},{"issue":"2","key":"key20241203121637_B2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1517\/14740338.2015.995088","article-title":"Why are anti-obesity drugs stigmatized?","volume":"14","author":"Halpern","year":"2015","unstructured":"2. Halpern B, Halpern A. Why are anti-obesity drugs stigmatized? Expert Opin Drug Saf. 2015;14(2):185-9. doi: 10.1517\/14740338.2015.995088.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"key20241203121637_B3","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12609","article-title":"Use of medications associated with weight change among participants in the All of Us research programme","volume":"13","author":"Almazan","year":"2023","unstructured":"3. Almazan E, Schwartz JL, Gudzune KA. Use of medications associated with weight change among participants in the All of Us research programme. Clin Obes. 2023;13(5):e12609. doi: 10.1111\/cob.12609.","journal-title":"Clin Obes"},{"issue":"8","key":"key20241203121637_B4","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/oby.21136","article-title":"Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010","volume":"23","author":"Xia","year":"2015","unstructured":"4. Xia Y, Kelton CM, Guo JJ, Bian B, Heaton PC. Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010. Obesity (Silver Spring). 2015;23(8):1721-8. doi: 10.1002\/oby.21136.","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"key20241203121637_B5","doi-asserted-by":"crossref","DOI":"10.20945\/2359-4292-2023-0174","article-title":"\"Anti-obesity medications\" or \"medications to treat obesity\" instead of \"weight loss drugs\" - why language matters - an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM)","volume":"67","author":"Halpern","year":"2023","unstructured":"5. Halpern B, Mancini MC, van de Sande-Lee S, Miranda PAC. \"Anti-obesity medications\" or \"medications to treat obesity\" instead of \"weight loss drugs\" - why language matters - an official statement of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM). Arch Endocrinol Metab. 2023;67(4):e230174. doi: 10.20945\/2359-4292-2023-0174.","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"key20241203121637_B6","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-023-01233-4","article-title":"Pharmacotherapy for obesity: moving towards efficacy improvement","volume":"16","author":"Coutinho","year":"2024","unstructured":"6. Coutinho W, Halpern B. Pharmacotherapy for obesity: moving towards efficacy improvement. Diabetol Metab Syndr. 2024;16(1):6. doi: 10.1186\/s13098-023-01233-4.","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"key20241203121637_B7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1124\/pr.59.2.2","article-title":"Pharmacological treatment of the overweight patient","volume":"59","author":"Bray","year":"2007","unstructured":"7. Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev. 2007;59(2):151-84. doi: 10.1124\/pr.59.2.2.","journal-title":"Pharmacol Rev"},{"key":"key20241203121637_B8","author":"Brasil","unstructured":"8. Brasil. Minist\u00e9rio da Sa\u00fade. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Resolu\u00e7\u00e3o - RDC n\u00ba 58, de 5 de setembro de 2007. Available from: https:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/anvisa\/2007\/rdc0058_05_09_2007.html. Accessed on: Jun 2024.","journal-title":"Resolu\u00e7\u00e3o - RDC n\u00ba 58, de 5 de setembro de 2007"},{"issue":"6","key":"key20241203121637_B9","first-page":"369","article-title":"The long-term outcomes of sibutramine effectiveness on weight (LOSE weight) study: Evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization","volume":"10","author":"Porter","year":"2004","unstructured":"9. Porter JAR, Marsha A, Conner DA, Lanty FA, Vogel EA, Gay EC, et al. The long-term outcomes of sibutramine effectiveness on weight (LOSE weight) study: Evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care. 2004;10(6):369-76.","journal-title":"Am J Manag Care"},{"key":"key20241203121637_B10","unstructured":"10. Sibutramina [bula]. Brasil. Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Consultas. [Internet]. Available from: https:\/\/consultas.anvisa.gov.br\/#\/bulario\/q\/?nomeProduto=CLORIDRATO%20DE%20SIBUTRAMINA. Accessed on: Jun 2024.","journal-title":"Sibutramina [bula]"},{"issue":"9","key":"key20241203121637_B11","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archinte.164.9.994","article-title":"The efficacy and safety of sibutramine for weight loss: a systematic review","volume":"164","author":"Arterburn","year":"2004","unstructured":"11. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med. 2004;164(9):994-1003. doi: 10.1001\/archinte.164.9.994.","journal-title":"Arch Intern Med"},{"issue":"3","key":"key20241203121637_B12","article-title":"Long-term pharmacotherapy for obesity and overweight","volume":"2003","author":"Padwal","year":"2004","unstructured":"12. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2004;2003(3):CD004094. doi: 10.1002\/14651858.CD004094.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9248","key":"key20241203121637_B13","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(00)03491-7","article-title":"Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance","volume":"356","author":"James","year":"2000","unstructured":"13. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, R\u00f6ssner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000;356(9248):2119-25. doi: 10.1016\/s0140-6736(00)03491-7.","journal-title":"Lancet"},{"issue":"7631","key":"key20241203121637_B14","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","article-title":"Long term pharmacotherapy for obesity and overweight: updated meta-analysis","volume":"335","author":"Rucker","year":"2007","unstructured":"14. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;335(7631):1194-9. doi: 10.1136\/bmj.39385.413113.25.","journal-title":"BMJ"},{"issue":"4","key":"key20241203121637_B15","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1210\/jc.2006-0264","article-title":"The effect of sibutramine on energy expenditure and body composition in obese adolescents","volume":"92","author":"Van Mil","year":"2007","unstructured":"15. Van Mil EG, Westerterp KR, Kester AD, Delemarre-van de Waal HA, Gerver WJ, Saris WH. The effect of sibutramine on energy expenditure and body composition in obese adolescents. J Clin Endocrinol Metab. 2007;92(4):1409-14. doi: 10.1210\/jc.2006-0264.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20241203121637_B16","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1053\/j.gastro.2008.07.009","article-title":"A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults","volume":"135","author":"Grudell","year":"2008","unstructured":"16. Grudell AB, Sweetser S, Camilleri M, Eckert DJ, Vazquez-Roque MI, Carlson PJ, et al. A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults. Gastroenterology. 2008;135(4):1142-54. doi: 10.1053\/j.gastro.2008.07.009.","journal-title":"Gastroenterology"},{"key":"key20241203121637_B17","first-page":"S38","article-title":"Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal\/visceral fat reduction?","volume":"22","author":"Van Gaal","year":"1998","unstructured":"17. Van Gaal LF, Wauters MA, Peiffer FW, De Leeuw IH. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal\/visceral fat reduction? Int J Obes Relat Metab Disord. 1998; 22 Suppl 1:S38-S40; discussion S41-2.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"7","key":"key20241203121637_B18","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","article-title":"Meta-analysis: pharmacologic treatment of obesity","volume":"142","author":"Li","year":"2005","unstructured":"18. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-46. doi: 10.7326\/0003-4819-142-7-200504050-00012.","journal-title":"Ann Intern Med"},{"issue":"1","key":"key20241203121637_B19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/diacare.26.1.125","article-title":"A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin","volume":"26","author":"McNulty","year":"2003","unstructured":"19. McNulty SJ, Ur E, Williams G; Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care. 2003;26(1):125-31. doi: 10.2337\/diacare.26.1.125.","journal-title":"Diabetes Care"},{"issue":"1","key":"key20241203121637_B20","first-page":"441","article-title":"The use of sibutramine in the management of obesity and related disorders: An update","volume":"5","author":"Tziomalos","year":"2009","unstructured":"20. Tziomalos K, Krassas GE, Tzotzas E. The use of sibutramine in the management of obesity and related disorders: An update. Vasc Health Risk Manag. 2009;5(1):441-52. doi: 10.2147\/vhrm.s4027.","journal-title":"Vasc Health Risk Manag"},{"issue":"1","key":"key20241203121637_B21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.ijo.0803363","article-title":"The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea","volume":"31","author":"Yee","year":"2007","unstructured":"21. Yee BJ, Phillips CL, Banerjee D, Caterson I, Hedner JA, Grunstein RR. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. Int J Obes (Lond). 2007;31(1):161-8. doi: 10.1038\/sj.ijo.0803363.","journal-title":"Int J Obes (Lond)"},{"key":"key20241203121637_B22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1183\/09031936.00167308","article-title":"Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients","volume":"34","author":"Ferland","year":"2009","unstructured":"22. Ferland A, Poirier P, S\u00e9ri\u00e8s F. Sibutramine versus continuous positive airway pressure in obese obstructive sleep apnoea patients. Eur Resp J. 2009;34:694-701. doi: 10.1183\/09031936.00167308.","journal-title":"Eur Resp J"},{"issue":"5","key":"key20241203121637_B23","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0015-0282(03)02162-9","article-title":"Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome","volume":"80","author":"Sabuncu","year":"2003","unstructured":"23. Sabuncu T, Harma M, Harma M, Nazligul Y, Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil Steril. 2003;80(5):1199-204. doi: 10.1016\/s0015-0282(03)02162-9.","journal-title":"Fertil Steril"},{"issue":"4","key":"key20241203121637_B24","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/sj.ijo.0803777","article-title":"Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study","volume":"32","author":"Florakis","year":"2008","unstructured":"24. Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, et al. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Int J Obes (Lond). 2008;32(4):692-9. doi: 10.1038\/sj.ijo.0803777.","journal-title":"Int J Obes (Lond)"},{"issue":"4","key":"key20241203121637_B25","first-page":"324","article-title":"Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks","volume":"4","author":"Hainerov\u00e1","year":"2011","unstructured":"25. Hainerov\u00e1 IA, Zamrazilov\u00e1 H, Sedl\u00e1ckov\u00e1 D, Hainer V. Hypogonadotropic hypogonadism in a homozygous MC4R mutation carrier and the effect of sibutramine treatment on body weight and obesity-related health risks. Obes Facts. 2011;4(4):324-8. doi: 10.1159\/000330763.","journal-title":"Obes Facts"},{"issue":"3","key":"key20241203121637_B26","first-page":"189","article-title":"The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis","volume":"12","author":"Sabuncu","year":"2003","unstructured":"26. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol. 2003;12(3):189-92.","journal-title":"Rom J Gastroenterol"},{"issue":"9","key":"key20241203121637_B27","first-page":"875","article-title":"Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo","volume":"7","author":"Samsa","year":"2001","unstructured":"27. Samsa GP, Kolotkin RL, Williams GR, Nguyen MH, Mendel CM. Effect of moderate weight loss on health-related quality of life: an analysis of combined data from 4 randomized trials of sibutramine vs placebo. Am J Manag Care. 2001;7(9):875-83.","journal-title":"Am J Manag Care"},{"issue":"10","key":"key20241203121637_B28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects","volume":"363","author":"James","year":"2010","unstructured":"28. James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. N Engl J Med. 2010;363(10):905-17. doi: 10.1056\/NEJMoa1003114.","journal-title":"N Engl J Med"},{"key":"key20241203121637_B29","first-page":"S12","article-title":"Mode of action of orlistat","volume":"21","author":"Guerciolini","year":"1997","unstructured":"29. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21 Suppl 3:S12-23.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"24","key":"key20241203121637_B30","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.2165\/00003495-200464240-00010","article-title":"Orlistat: a review of its use in the management of patients with obesity","volume":"64","author":"Curran","year":"2004","unstructured":"30. Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs. 2004;64(24):2845-64. doi: 10.2165\/00003495-200464240-00010.","journal-title":"Drugs"},{"issue":"1","key":"key20241203121637_B31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00002018-200831010-00005","article-title":"Orlistat-associated adverse effects and drug interactions: a critical review","volume":"31","author":"Filippatos","year":"2008","unstructured":"31. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31(1):53-65. doi: 10.2165\/00002018-200831010-00005.","journal-title":"Drug Saf"},{"issue":"2","key":"key20241203121637_B32","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1523-1755.2004.00790.x","article-title":"Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion","volume":"66","author":"Ferraz","year":"2004","unstructured":"32. Ferraz RR, Tiselius HG, Heilberg IP. Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. Kidney Int. 2004;66(2):676-82. doi: 10.1111\/j.1523-1755.2004.00790.x.","journal-title":"Kidney Int"},{"issue":"1","key":"key20241203121637_B33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.ajkd.2006.10.004","article-title":"Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor","volume":"49","author":"Singh","year":"2007","unstructured":"33. Singh A, Sarkar SR, Gaber LW, Perazella MA. Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor. Am J Kidney Dis. 2007;49(1):153-7. doi: 10.1053\/j.ajkd.2006.10.004.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"key20241203121637_B34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","unstructured":"34. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-62. doi: 10.1210\/jc.2014-3415.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"key20241203121637_B35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","unstructured":"35. Torgerson JS, Hauptman J, Boldrin MN, Sj\u00f6str\u00f6m L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155-61. doi: 10.2337\/diacare.27.1.155.","journal-title":"Diabetes Care"},{"issue":"8","key":"key20241203121637_B36","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/sj.ijo.0801639","article-title":"Influence of orlistat on bone turnover and body composition","volume":"25","author":"Gotfredsen","year":"2001","unstructured":"36. Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord. 2001;25(8):1154-60. doi: 10.1038\/sj.ijo.0801639.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"12","key":"key20241203121637_B37","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/sj.ijo.0801443","article-title":"Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns","volume":"24","author":"Karhunen","year":"2000","unstructured":"37. Karhunen L, Franssila-Kallunki A, Rissanen P, Valve R, Kolehmainen M, Rissanen A, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Relat Metab Disord. 2000;24(12):1567-72. doi: 10.1038\/sj.ijo.0801443.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"4","key":"key20241203121637_B38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1463-1326.2008.00970.x","article-title":"Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss","volume":"11","author":"Jacob","year":"2009","unstructured":"38. Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11(4):361-71. doi: 10.1111\/j.1463-1326.2008.00970.x.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"key20241203121637_B39","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/obr.12318","article-title":"Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Aldekhail","year":"2015","unstructured":"39. Aldekhail NM, Logue J, McLoone P, Morrison DS. Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2015;16(12):1071-80. doi: 10.1111\/obr.12318.","journal-title":"Obes Rev"},{"issue":"11","key":"key20241203121637_B40","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/sj.ijo.0801814","article-title":"The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study","volume":"25","author":"Mules","year":"2001","unstructured":"40. Mules E, Kolanowski J, Scheen A, Van Gaal L; ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord. 2001;25(11):1713-21. doi: 10.1038\/sj.ijo.0801814.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"1","key":"key20241203121637_B41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group","volume":"8","author":"R\u00f6ssner","year":"2000","unstructured":"41. R\u00f6ssner S, Sj\u00f6str\u00f6m L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res. 2000;8(1):49-61. doi: 10.1038\/oby.2000.8.","journal-title":"Obes Res"},{"issue":"9123","key":"key20241203121637_B42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.","volume":"352","author":"Sj\u00f6str\u00f6m","year":"1998","unstructured":"42. Sj\u00f6str\u00f6m L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352(9123):167-72. doi: 10.1016\/s0140-6736(97)11509-4.","journal-title":"Lancet"},{"issue":"6","key":"key20241203121637_B43","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1111\/jog.15211","article-title":"Effects of oral contraceptives plus orlistat in patients with polycystic ovary syndrome and overweight\/obesity: A meta-analysis","volume":"48","author":"Chen","year":"2022","unstructured":"43. Chen Z, Cai Z. Effects of oral contraceptives plus orlistat in patients with polycystic ovary syndrome and overweight\/obesity: A meta-analysis. J Obstet Gynaecol Res. 2022;48(6):1399-408. doi: 10.1111\/jog.15211.","journal-title":"J Obstet Gynaecol Res"},{"issue":"5","key":"key20241203121637_B44","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s13224-018-1140-6","article-title":"Effect of Orlistat Versus Metformin in Various Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Randomized Control Trials","volume":"68","author":"Panda","year":"2018","unstructured":"44. Panda SR, Jain M, Jain S, Saxena R, Hota S. Effect of Orlistat Versus Metformin in Various Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Randomized Control Trials. J Obstet Gynaecol India. 2018; 68(5):336-43. doi: 10.1007\/s13224-018-1140-6.","journal-title":"J Obstet Gynaecol India"},{"issue":"1","key":"key20241203121637_B45","first-page":"90","article-title":"Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"9","author":"Wang","year":"2018","unstructured":"45. Wang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J. Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2018;9(1):90-6. doi: 10.3892\/br.2018.1100.","journal-title":"Biomed Rep"},{"key":"key20241203121637_B46","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00070","article-title":"Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review","volume":"11","author":"Pan","year":"2020","unstructured":"46. Pan CS, Stanley TL. Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. Front Endocrinol (Lausanne). 2020 Feb 21;11:70. doi: 10.3389\/fendo.2020.00070.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"key20241203121637_B47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/oby.2000.8","article-title":"Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group","volume":"8","author":"R\u00f6ssner","year":"2000","unstructured":"47. R\u00f6ssner S, Sj\u00f6str\u00f6m L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res. 2000;8(1):49-61. doi: 10.1038\/oby.2000.8.","journal-title":"Obes Res"},{"key":"key20241203121637_B48","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2014-eular.2440","article-title":"Influence by Orlistat Therapy Obesity on Clinical Symptoms of Knee Osteoarthritis in Women with Overweight","volume":"73","author":"Strebkova","year":"2014","unstructured":"48. Strebkova E, Solovyeva I, Sharapova E, Mkrtumyan A, Alekseeva L, Nasonov E. Influence by Orlistat Therapy Obesity on Clinical Symptoms of Knee Osteoarthritis in Women with Overweight. Ann Rheum Dis. 2014;73:253. Doi: 10.1136\/annrheumdis-2014-eular.2440.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"key20241203121637_B49","doi-asserted-by":"crossref","DOI":"10.4172\/2161-0533.1000232","article-title":"Long Term Effect of Weight Change on Clinical Manifestation of Knee Osteoarthritis among Women Treated with Orlistat","volume":"6","author":"Goldenshluger","year":"2017","unstructured":"49. Goldenshluger M, Reitblat O, Schneider R, Lerman TT, Barkay G, Reitblat T. Long Term Effect of Weight Change on Clinical Manifestation of Knee Osteoarthritis among Women Treated with Orlistat. Orthop Muscular Syst. 2017;6(2). doi: 10.4172\/2161-0533.1000232.","journal-title":"Orthop Muscular Syst"},{"issue":"5","key":"key20241203121637_B50","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2337\/diabetes.53.5.1187","article-title":"One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes","volume":"53","author":"Degn","year":"2004","unstructured":"50. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53(5):1187-94. doi: 10.2337\/diabetes.53.5.1187.","journal-title":"Diabetes"},{"issue":"6","key":"key20241203121637_B51","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","unstructured":"51. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-57. doi: 10.1053\/j.gastro.2007.03.054.","journal-title":"Gastroenterology"},{"issue":"1","key":"key20241203121637_B52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","unstructured":"52. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi: 10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20241203121637_B53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/osp4.84","article-title":"Liraglutide for weight management: a critical review of the evidence","volume":"3","author":"Mehta","year":"2017","unstructured":"53. Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3-14. doi: 10.1002\/osp4.84.","journal-title":"Obes Sci Pract"},{"issue":"9701","key":"key20241203121637_B54","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","unstructured":"54. Astrup A, R\u00f6ssner S, van Gaal L, Rissanen A, Niskanen L, al Hakim M, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-16. doi: 10.1016\/S0140-6736(09)61375-1.","journal-title":"Lancet"},{"issue":"6","key":"key20241203121637_B55","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","unstructured":"55. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36(6):843-54. doi: 10.1038\/ijo.2011.158.","journal-title":"Int J Obes (Lond)"},{"issue":"10077","key":"key20241203121637_B56","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","unstructured":"56. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-409. doi: 10.1016\/S0140-6736(17)30069-7.","journal-title":"Lancet"},{"issue":"11","key":"key20241203121637_B57","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","unstructured":"57. Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale PM, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-51. doi: 10.1038\/ijo.2013.120.","journal-title":"Int J Obes (Lond)"},{"issue":"18","key":"key20241203121637_B58","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined","volume":"384","author":"Lundgren","year":"2021","unstructured":"58. Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021;384(18):1719-30. doi: 10.1056\/NEJMoa2028198.","journal-title":"N Engl J Med"},{"issue":"9","key":"key20241203121637_B59","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","unstructured":"59. Neeland IJ, Marso SP, Ayers CR, Lewis B, Oslica R, Francis W, et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021;9(9):595-605. doi: 10.1016\/S2213-8587(21)00179-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"key20241203121637_B60","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-3094","article-title":"Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein","volume":"9","author":"Gao","year":"2021","unstructured":"60. Gao F, Wu D, Guo L, Wang L, Hao M, Li L, et al. Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein. Ann Transl Med 2021;9(14):1157. doi: 10.21037\/atm-21-3094.","journal-title":"Ann Transl Med"},{"issue":"1","key":"key20241203121637_B61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-36602-6","article-title":"GLP-1 receptor agonist protects palmitate-induced insulin resistance in skeletal muscle cells by up-regulating sestrin2 to promote autophagy","volume":"13","author":"Tian","year":"2023","unstructured":"61. Tian X, Gao Y, Kong M, Zhao L, Xing E, Sun Q, et al. GLP-1 receptor agonist protects palmitate-induced insulin resistance in skeletal muscle cells by up-regulating sestrin2 to promote autophagy. Sci Rep. 2023;13(1):9446. doi: 10.1038\/s41598-023-36602-6.","journal-title":"Sci Rep"},{"key":"key20241203121637_B62","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.2337\/dc13-0354","article-title":"Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals with Prediabetes","volume":"36","author":"Kim","year":"2013","unstructured":"62. Kim SH, Abbasi F, Lamendola C, Liu A, Ariel D, Schaaf P, et al. Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals with Prediabetes. Diabetes Care. 2013;36:3276-82. doi: 10.2337\/dc13-0354.","journal-title":"Diabetes Care"},{"issue":"1","key":"key20241203121637_B63","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-023-01121-x","article-title":"2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes","volume":"15","author":"Bertoluci","year":"2023","unstructured":"63. Bertoluci MC, Silva J\u00fanior WS, Valente F, Araujo LR, Lyra R, Castro JJ, et al. 2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes. Diabetol Metab Syndr. 2023;15(1):160. doi: 10.1186\/s13098-023-01121-x.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"key20241203121637_B64","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4155\/cli.11.166","article-title":"Design, findings and implications of liraglutide Phase III clinical trial program","volume":"2","author":"Bode","year":"2012","unstructured":"64. Bode BW. Design, findings and implications of liraglutide Phase III clinical trial program. Clin Invest. 2012;2(1):59-72. doi: 10.4155\/CLI.11.166.","journal-title":"Clin Invest"},{"key":"key20241203121637_B65","first-page":"18","article-title":"Liraglutide in clinical practice: insights from LEAD programme","volume":"58","author":"Sethi","year":"2010","unstructured":"65. Sethi B, Viswanathan V, Kumar A, Chatterjee S, Chandalia H. Liraglutide in clinical practice: insights from LEAD programme. J Assoc Physicians India. 2010;58:18-22.","journal-title":"J Assoc Physicians India"},{"issue":"7","key":"key20241203121637_B66","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of Liraglutide for Weight Loss Among Patients with Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial","volume":"314","author":"Davies","year":"2015","unstructured":"66. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al. Efficacy of Liraglutide for Weight Loss Among Patients with Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015; 314(7):687-99. doi: 10.1001\/jama.2015.9676.","journal-title":"JAMA"},{"key":"key20241203121637_B67","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13300-016-0180-0","article-title":"Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review","volume":"7","author":"Ostawal","year":"2016","unstructured":"67. Ostawal A, Mocevic E, Kragh N, Xu W. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review. Diabetes Ther. 2016;7:411-38. doi: 10.1007\/s13300-016-0180-0.","journal-title":"Diabetes Ther"},{"issue":"2","key":"key20241203121637_B68","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12325-017-0652-2","article-title":"Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study","volume":"35","author":"Lapolla","year":"2018","unstructured":"68. Lapolla A, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, et. al. Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. Adv Ther. 2018;35(2):243-53. doi: 10.1007\/s12325-017-0652-2.","journal-title":"Adv Ther"},{"key":"key20241203121637_B69","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108871","article-title":"Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review","volume":"177","author":"Yousef","year":"2021","unstructured":"69. Yousef CC, Thomas A, Al Matar M, Ghandoura L, Aldossary I, Almuhanna SM, et al. Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review. Diabetes Res Clin Pract. 2021;177:108871. doi: 10.1016\/j.diabres.2021.108871.","journal-title":"Diabetes Res Clin Pract"},{"key":"key20241203121637_B70","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-019-0954-6","article-title":"Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1\/2 pathway","volume":"18","author":"Wu","year":"2019","unstructured":"70. Wu YR, Shi XY, Ma CY, Zhang Y, Xu RX, Li JJ. Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1\/2 pathway. Cardiovasc Diabetol. 2019;18:146. doi: 10.1186\/s12933-019-0954-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"key20241203121637_B71","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc20-1843","article-title":"Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients with Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin\/Kexin Type 9 Expression","volume":"44","author":"Verg\u00e8s","year":"2021","unstructured":"71. Verg\u00e8s B, Duvillard L, Barros JPP, Bouillet B, Baillot-Rudoni S, Rouland A, et al. Liraglutide Increases the Catabolism of Apolipoprotein B100-Containing Lipoproteins in Patients with Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin\/Kexin Type 9 Expression. Diabetes Care. 2021;44(4):1027-37. doi: 10.2337\/dc20-1843.","journal-title":"Diabetes Care"},{"key":"key20241203121637_B72","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/dom.14328","article-title":"Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes","volume":"23","author":"Taskinen","year":"2021","unstructured":"72. Taskinen MR, Bj\u00f6rnson E, Matikainen N, S\u00f6derlund S, Pietil\u00e4inen KH, Ainola M, et al. Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes. Diabetes Obes Metab. 2021;23:1191-201. doi: 10.1111\/dom.14328.","journal-title":"Diabetes Obes Metab"},{"key":"key20241203121637_B73","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1161\/ATVBAHA.118.310990","article-title":"Liraglutide reduces postprandial hyperlipidemia by increasing apoB48 (apolipoprotein B48) catabolism and by reducing apoB48 production in patients with type 2 diabetes mellitus","volume":"38","author":"Verg\u00e8s","year":"2018","unstructured":"73. Verg\u00e8s B, Duvillard L, Barros JPP, Bouillet B, Baillot-Rudoni S, Rouland A, et al. Liraglutide reduces postprandial hyperlipidemia by increasing apoB48 (apolipoprotein B48) catabolism and by reducing apoB48 production in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2018;38:2198-206. doi: 10.1161\/ATVBAHA.118.310990.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"key20241203121637_B74","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/dom.13487","article-title":"Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study","volume":"21","author":"Matikainen","year":"2019","unstructured":"74. Matikainen N, S\u00f6derlund S, Bj\u00f6rnson E, Pietil\u00e4inen K, Hakkarainen A, Lundbom N, et al. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. Diabetes Obes Metab. 2019;21(1):84-94. doi: 10.1111\/dom.13487.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"key20241203121637_B75","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2337\/dc14-1958","article-title":"Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes","volume":"38","author":"Lovshin","year":"2015","unstructured":"75. Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care. 2015;38(1):132-9. doi: 10.2337\/dc14-1958.","journal-title":"Diabetes Care"},{"issue":"18","key":"key20241203121637_B76","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways","volume":"117","author":"Ban","year":"2008","unstructured":"76. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340-50. doi: 10.1161\/CIRCULATIONAHA.107.739938.","journal-title":"Circulation"},{"issue":"1","key":"key20241203121637_B77","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-016-0490-6","article-title":"Differential effects of glucagon-like peptide-1 receptor agonists on heart rate","volume":"16","author":"Lorenz","year":"2017","unstructured":"77. Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A, et al. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017;16(1):6. doi: 10.1186\/s12933-016-0490-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"key20241203121637_B78","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jdiacomp.2014.01.009","article-title":"Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials","volume":"28","author":"Fonseca","year":"2014","unstructured":"78. Fonseca VA, DeVries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014;28(3):399-405. doi: 10.1016\/j.jdiacomp.2014.01.009.","journal-title":"J Diabetes Complications"},{"issue":"4","key":"key20241203121637_B79","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","unstructured":"79. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. doi: 10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"issue":"1","key":"key20241203121637_B80","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2337\/dc16-1580","article-title":"Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study","volume":"40","author":"Kumarathurai","year":"2017","unstructured":"80. Kumarathurai P, Anholm C, Larsen BS, Olsen RH, Madsbad S, Kristiansen O, et al. Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study. Diabetes Care. 2017;40(1):117-24. doi: 10.2337\/dc16-1580.","journal-title":"Diabetes Care"},{"issue":"1","key":"key20241203121637_B81","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/jch.13447","article-title":"Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes","volume":"21","author":"Wijkman","year":"2019","unstructured":"81. Wijkman MO, Dena M, Dahlqvist S, Sofizadeh S, Hirsch I, Tuomilehto J, et al. Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes. J Clin Hyperten (Greenwich). 2019;21(1):105-15. doi: 10.1111\/jch.13447.","journal-title":"J Clin Hyperten (Greenwich)"},{"issue":"1","key":"key20241203121637_B82","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-018-0332-5","article-title":"Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials","volume":"19","author":"Zhao","year":"2019","unstructured":"82. Zhao X, Huang K, Zheng M, Duan J. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. BMC Endocr Disord. 2019;19(1):4. doi: 10.1186\/s12902-018-0332-5.","journal-title":"BMC Endocr Disord"},{"issue":"7","key":"key20241203121637_B83","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11892-023-01510-6","article-title":"Sleep Apnea, Obesity, and Diabetes - an Intertwined Trio","volume":"23","author":"Kurnool","year":"2023","unstructured":"83. Kurnool S, McCowen KC, Bernstein NA, Malhotra A. Sleep Apnea, Obesity, and Diabetes - an Intertwined Trio. Curr Diab Rep. 2023;23(7):165-71. doi: 10.1007\/s11892-023-01510-6.","journal-title":"Curr Diab Rep"},{"issue":"8","key":"key20241203121637_B84","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","unstructured":"84. Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-9. doi: 10.1038\/ijo.2016.52.","journal-title":"Int J Obes (Lond)"},{"issue":"5","key":"key20241203121637_B85","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s11325-022-02768-y","article-title":"Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea","volume":"27","author":"Jiang","year":"2023","unstructured":"85. Jiang W, Li W, Cheng J, Li W, Cheng F. Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. Sleep Breath. 2023;27(5):1687-94. doi: 10.1007\/s11325-022-02768-y.","journal-title":"Sleep Breath"},{"issue":"8","key":"key20241203121637_B86","doi-asserted-by":"crossref","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists","volume":"105","author":"Cena","year":"2020","unstructured":"86. Cena H, Chiovato L, Nappi RE. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. J Clin Endocrinol Metab. 2020;105(8):e2695-709. doi: 10.1210\/clinem\/dgaa285.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"key20241203121637_B87","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00404-015-3976-7","article-title":"A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries","volume":"293","author":"Niafar","year":"2016","unstructured":"87. Niafar M, Pourafkari L, Porhomayon J, Nader N. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries. Arch Gynecol Obstet. 2016;293(3):509-15. doi: 10.1007\/s00404-015-3976-7.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"key20241203121637_B88","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40618-021-01666-6","article-title":"The effectiveness and safety of liraglutide in treating overweight\/obese patients with polycystic ovary syndrome: a meta-analysis","volume":"45","author":"Ge","year":"2022","unstructured":"88. Ge JJ, Wang DJ, Song W, Shen SM, Ge WH. The effectiveness and safety of liraglutide in treating overweight\/obese patients with polycystic ovary syndrome: a meta-analysis. J Endocrinol Invest. 2022;45(2):261-73. doi: 10.1007\/s40618-021-01666-6.","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"key20241203121637_B89","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.rbmo.2017.03.023","article-title":"Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial","volume":"35","author":"Nylander","year":"2017","unstructured":"89. Nylander M, Frossing S, Clausen HV, Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017;35(1):121-7. doi: 10.1016\/j.rbmo.2017.03.023.","journal-title":"Reprod Biomed Online"},{"issue":"2","key":"key20241203121637_B90","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch","year":"2022","unstructured":"90. Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril. 2022;118(2):371-81. doi: 10.1016\/j.fertnstert.2022.04.027.","journal-title":"Fertil Steril"},{"issue":"1","key":"key20241203121637_B91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-18-0175","article-title":"Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study","volume":"179","author":"Salamun","year":"2018","unstructured":"91. Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179(1):1-11. doi: 10.1530\/EJE-18-0175.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"key20241203121637_B92","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1172\/JCI610","article-title":"Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line","volume":"101","author":"Beak","year":"1998","unstructured":"92. Beak SA, Heath MM, Small CJ, Morgan DG, Ghatei MA, Taylor AD, et al. Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line. J Clin Invest. 1998;101(6):1334-41. doi: 10.1172\/JCI610.","journal-title":"J Clin Invest"},{"issue":"6","key":"key20241203121637_B93","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/andr.12099","article-title":"Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism","volume":"3","author":"Giagulli","year":"2015","unstructured":"93. Giagulli VA, Carbone MD, Ramunni MI, Licchelli B, De Pergola G, Sabba C, et al. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. Andrology. 2015;3(6):1094-103. doi: 10.1111\/andr.12099.","journal-title":"Andrology"},{"issue":"3","key":"key20241203121637_B94","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EC-18-0514","article-title":"Effects of liraglutide on obesity-associated functional hypogonadism in men","volume":"8","author":"Jensterle","year":"2019","unstructured":"94. Jensterle M, Podbregar A, Goricar K, Gregoric N, Janez A. Effects of liraglutide on obesity-associated functional hypogonadism in men. Endocr Connect. 2019;8(3):195-202. doi: 10.1530\/EC-18-0514.","journal-title":"Endocr Connect"},{"issue":"2","key":"key20241203121637_B95","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12020672","article-title":"Sexual and Reproductive Outcomes in Obese Fertile Men with Functional Hypogonadism after Treatment with Liraglutide: Preliminary Results","volume":"12","author":"La Vignera","year":"2023","unstructured":"95. La Vignera S, Condorelli RA, Calogero AE, Cannarella R, Aversa A. Sexual and Reproductive Outcomes in Obese Fertile Men with Functional Hypogonadism after Treatment with Liraglutide: Preliminary Results. J Clin Med. 2023;12(2):672. doi: 10.3390\/jcm12020672.","journal-title":"J Clin Med"},{"issue":"1","key":"key20241203121637_B96","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD","volume":"107","author":"Patel Chavez","year":"2022","unstructured":"96. Patel Chavez C, Cusi K, Kadiyala S. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. J Clin Endocrinol Metab. 2022;107(1):29-38. doi: 10.1210\/clinem\/dgab578.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"key20241203121637_B97","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1210\/jc.2015-3906","article-title":"Mechanisms of Action of Liraglutide in Patients with Type 2 Diabetes Treated with High-Dose Insulin","volume":"101","author":"Vanderheiden","year":"2016","unstructured":"97. Vanderheiden A, Harrison LB, Warshauer JT, Adams-Huet B, Li X, Yuan Q, et al. Mechanisms of Action of Liraglutide in Patients with Type 2 Diabetes Treated with High-Dose Insulin. J Clin Endocrinol Metab. 2016;101(4):1798-806. doi: 10.1210\/jc.2015-3906.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"key20241203121637_B98","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease","volume":"69","author":"Yan","year":"2019","unstructured":"98. Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, et al. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Hepatology. 2019;69(6):2414-26. doi: 10.1002\/hep.30320.","journal-title":"Hepatology"},{"key":"key20241203121637_B99","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","unstructured":"99. Guo W, Tian W, Lin L, Xu X. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial. Diabetes Res Clin Pract. 2020;170:108487. doi: 10.1016\/j.diabres.2020.108487.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"key20241203121637_B100","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.13053","article-title":"Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial","volume":"20","author":"Frossing","year":"2018","unstructured":"100. Frossing S, Nylander M, Chabanova E, Frystyk J, Holst JJ, Kistorp C, et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes Obes Metab. 2018;20(1):215-8. doi: 10.1111\/dom.13053.","journal-title":"Diabetes Obes Metab"},{"issue":"10019","key":"key20241203121637_B101","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","unstructured":"101. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679-90. doi: 10.1016\/S0140-6736(15)00803-X.","journal-title":"Lancet"},{"issue":"1","key":"key20241203121637_B102","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","unstructured":"102. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi: 10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"issue":"4","key":"key20241203121637_B103","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/cob.12146","article-title":"Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management","volume":"6","author":"Kolotkin","year":"2016","unstructured":"103. Kolotkin RL, Fujioka K, Wolden ML, Brett JH, Bjorner JB. Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. Clin Obes. 2016;6(4):233-42. doi: 10.1111\/cob.12146.","journal-title":"Clin Obes"},{"issue":"10077","key":"key20241203121637_B104","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","unstructured":"104. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-409. doi: 10.1016\/S0140-6736(17)30069-7.","journal-title":"Lancet"},{"issue":"1","key":"key20241203121637_B105","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot","year":"2022","unstructured":"105. Meurot C, Martin C, Sudre L, Breton J, Bougault C, Rattenbach R, et al. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep. 2022;12(1):1567. doi: 10.1038\/s41598-022-05323-7.","journal-title":"Sci Rep"},{"key":"key20241203121637_B106","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jot.2022.02.001","article-title":"Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: A new opportunity?","volume":"32","author":"Meurot","year":"2022","unstructured":"106. Meurot C, Jacques C, Martin C, Sudre L, Breton J, Rattenbach R, et al. Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: A new opportunity? J Orthop Translat. 2022;32:121-9. doi: 10.1016\/j.jot.2022.02.001.","journal-title":"J Orthop Translat"},{"issue":"2","key":"key20241203121637_B107","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","article-title":"Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial","volume":"113","author":"Gudbergsen","year":"2021","unstructured":"107. Gudbergsen H, Overgaard A, Henriksen M, Wahrens EE, Bliddal H, Christensen R, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr. 2021;113(2):314-23. doi: 10.1093\/ajcn\/nqaa328.","journal-title":"Am J Clin Nutr"},{"issue":"8","key":"key20241203121637_B108","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1007\/s12325-022-02223-0","article-title":"A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches","volume":"39","author":"Mima","year":"2022","unstructured":"108. Mima A. A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches. Adv Ther. 2022;39(8):3488-500. doi: 10.1007\/s12325-022-02223-0.","journal-title":"Adv Ther"},{"issue":"9","key":"key20241203121637_B109","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","unstructured":"109. Mann JFE, Buse JB, Idorn T, Leiter LA, Pratley RE, Rasmussen S, et al. Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis. Diabetes Obes Metab. 2021;23(9):2058-66. doi: 10.1111\/dom.14443.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"key20241203121637_B110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2215\/CJN.11881019","article-title":"Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease","volume":"15","author":"Mann","year":"2020","unstructured":"110. Mann JFE, Fonseca VA, Poulter NR, Raz I, Idorn T, Rasmussen S, et al. Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clin J Am Soc Nephrol. 2020;15(4):465-73. doi: 10.2215\/CJN.11881019.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"key20241203121637_B111","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2337\/dc15-1025","article-title":"Safety and Efficacy of Liraglutide in Patients with Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial","volume":"39","author":"Idorn","year":"2016","unstructured":"111. Idorn T, Knop FK, Jorgensen MB, Jensen T, Resuli M, Hansen PM, et al. Safety and Efficacy of Liraglutide in Patients with Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. Diabetes Care. 2016;39(2):206-13. doi: 10.2337\/dc15-1025.","journal-title":"Diabetes Care"},{"issue":"3","key":"key20241203121637_B112","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28031369","article-title":"Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update","volume":"28","author":"Vandemark","year":"2023","unstructured":"112. Vandemark C, Nguyen J, Zhao ZQ. Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update. Molecules. 2023;28(3):1369. doi: 10.3390\/molecules28031369.","journal-title":"Molecules"},{"issue":"15","key":"key20241203121637_B113","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.118.036862","article-title":"Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use","volume":"138","author":"Verma","year":"2018","unstructured":"113. Verma S, Leiter LL, Mazer CD, Bain SC, Buse J, Marso S, et al. Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use. Circulation. 2018;138(15):1605-7. doi: 10.1161\/CIRCULATIONAHA.118.036862.","journal-title":"Circulation"},{"issue":"3","key":"key20241203121637_B114","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/dom.13125","article-title":"Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials","volume":"20","author":"Davies","year":"2018","unstructured":"114. Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018;20(3):734-9. doi: 10.1111\/dom.13125.","journal-title":"Diabetes Obes Metab"},{"key":"key20241203121637_B115","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","unstructured":"115. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. doi: 10.3389\/fendo.2019.00155.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"14","key":"key20241203121637_B116","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1523\/JNEUROSCI.6326-11.2012","article-title":"The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors","volume":"32","author":"Dickson","year":"2012","unstructured":"116. Dickson SL, Shirazi RH, Hansson C, Bergquist F, Nissbrandt H, Skibicka KP. The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors. J Neurosci. 2012;32(14):4812-20. doi: 10.1523\/JNEUROSCI.6326-11.2012.","journal-title":"J Neurosci"},{"issue":"3","key":"key20241203121637_B117","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2023","unstructured":"117. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2023;23(3):754-62. doi: 10.1111\/dom.14280.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"key20241203121637_B118","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/87551225221092681","article-title":"Once-Weekly Semaglutide for Weight Management: A Clinical Review","volume":"38","author":"Forbes","year":"2022","unstructured":"118. Forbes A, Huff J, Pritchard RI, Godfrey M. Once-Weekly Semaglutide for Weight Management: A Clinical Review. J Pharm Technol. 2022;38(4):239-46. doi: 10.1177\/87551225221092681.","journal-title":"J Pharm Technol"},{"issue":"11","key":"key20241203121637_B119","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","unstructured":"119. Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi: 10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"2","key":"key20241203121637_B120","doi-asserted-by":"crossref","first-page":"65","DOI":"10.15605\/jafes.037.02.14","article-title":"Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis","volume":"37","author":"Tan","year":"2022","unstructured":"120. Tan H, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022;37(2):65-72. doi: 10.15605\/jafes.037.02.14.","journal-title":"J ASEAN Fed Endocr Soc"},{"issue":"18","key":"key20241203121637_B121","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss","volume":"330","author":"Sodhi","year":"2023","unstructured":"121. Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-7. doi: 10.1001\/jama.2023.19574.","journal-title":"JAMA"},{"key":"key20241203121637_B122","volume-title":"Semaglutida (Wegovy) [bula]","year":"2024","unstructured":"122. Semaglutida (Wegovy) [bula]. Montes Claros: Novo Nordisk; 2024."},{"issue":"10148","key":"key20241203121637_B123","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","unstructured":"123. O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-49. doi: 10.1016\/S0140-6736(18)31773-2.","journal-title":"Lancet"},{"issue":"10278","key":"key20241203121637_B124","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","unstructured":"124. Davies M, Farch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-84. doi: 10.1016\/S0140-6736(21)00213-0.","journal-title":"Lancet"},{"issue":"14","key":"key20241203121637_B125","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity: The STEP 3 Randomized Clinical Trial","volume":"325","author":"Wadden","year":"2021","unstructured":"125. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403-13. doi: 10.1001\/jama.2021.1831.","journal-title":"JAMA"},{"issue":"14","key":"key20241203121637_B126","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial","volume":"325","author":"Rubino","year":"2021","unstructured":"126. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-25. doi: 10.1001\/jama.2021.3224.","journal-title":"JAMA"},{"issue":"10","key":"key20241203121637_B127","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","unstructured":"127. Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-91. doi: 10.1038\/s41591-022-02026-4.","journal-title":"Nat Med"},{"issue":"10","key":"key20241203121637_B128","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.2337\/dc21-1785","article-title":"Changes in Glucose Metabolism and Glycemic Status with Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants with Prediabetes in the STEP Program","volume":"45","author":"Perrealt","year":"2022","unstructured":"128. Perrealt L, Davies M, Frias JP, Laursen PN, Lingvay I, Machineni S, et al. Changes in Glucose Metabolism and Glycemic Status with Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants with Prediabetes in the STEP Program. Diabetes Care. 2022;45(10):2396-405. doi: 10.2337\/dc21-1785.","journal-title":"Diabetes Care"},{"key":"key20241203121637_B129","author":"McGowan","year":"2024","unstructured":"129. McGowan BM, Bruun JM, Capehorn M, Pedersen S, Pietil\u00e4inen KH, Muniraju HAK, et al. STEP 10 trial: semaglutide 2.4 mg provided a superior reduction vs placebo in body weight and reversion to normoglycaemia in participants with obesity and prediabetes. In: European Congress of Obesity, Veneza, 2024 May.","journal-title":"STEP 10 trial: semaglutide 2.4 mg provided a superior reduction vs placebo in body weight and reversion to normoglycaemia in participants with obesity and prediabetes"},{"key":"key20241203121637_B130","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.760153","article-title":"Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist with Both Injectable and Oral Formulations","volume":"12","author":"Meier","year":"2021","unstructured":"130. Meier JJ, Gallwitz B, Giorgino F. Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist with Both Injectable and Oral Formulations. Front Endocrinol (Lausanne). 2021;12:760153. doi: 10.3389\/fendo.2021.760153.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"key20241203121637_B131","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2023","unstructured":"131. Kosiborod MN, Bhatta M, Davies M, Deanfield JE, Garvey WT, Khalid U, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab. 2023;25(2):468-78. doi: 10.1111\/dom.14890.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"key20241203121637_B132","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12030772","article-title":"The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis","volume":"12","author":"Kennedy","year":"2023","unstructured":"132. Kennedy C, Hayes P, Salama S, Hennessy M, Federica F. The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis. J Clin Med. 2023;12(3):772. doi: 10.3390\/jcm12030772.","journal-title":"J Clin Med"},{"key":"key20241203121637_B133","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108935","article-title":"Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study","volume":"178","author":"Jensterle","year":"2021","unstructured":"133. Jensterle M, Ferjan S, Vovk A, Battelino T, Rizzo M, Jane\u017e A. Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study. Diabetes Res Clin Pract. 2021;178:108935. doi: 10.1016\/j.diabres.2021.108935.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"key20241203121637_B134","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.fertnstert.2023.07.025","article-title":"Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome","volume":"120","author":"Teede","year":"2023","unstructured":"134. Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023;120(4):767-93. doi: 10.1016\/j.fertnstert.2023.07.025.","journal-title":"Fertil Steril"},{"issue":"12","key":"key20241203121637_B135","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","unstructured":"135. Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-24. doi: 10.1056\/NEJMoa2028395.","journal-title":"N Engl J Med"},{"issue":"6","key":"key20241203121637_B136","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","unstructured":"136. Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjar MS, Krarup N, et al. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-22. doi: 10.1016\/S2468-1253(23)00068-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key20241203121637_B137","year":"2024","unstructured":"137. Effect of Subcutaneous Semaglutide 2.4 mg Once-weekly Compared to Placebo in Subjects with Obesity and Knee Osteoarthritis. In: European Congress of Obesity, Veneza, 2024.","journal-title":"Effect of Subcutaneous Semaglutide 2.4 mg Once-weekly Compared to Placebo in Subjects with Obesity and Knee Osteoarthritis"},{"issue":"8","key":"key20241203121637_B138","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/ckj\/sfac096","article-title":"Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice","volume":"15","author":"Bueno","year":"2022","unstructured":"138. Bueno BA, Soler MJ, Perez-Belmonte L, Millan AJ, Ruiz FR, Lucas MDG. Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice. Clin Kidney J. 2022;15(8):1593-600. doi: 10.1093\/ckj\/sfac096.","journal-title":"Clin Kidney J"},{"issue":"4","key":"key20241203121637_B139","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/dc22-1889","article-title":"Effects of Semaglutide on Albuminuria and Kidney Function in People with Overweight or Obesity with or Without Type 2 Diabetes: Exploratory Analysis from the STEP 1, 2, and 3 Trials","volume":"46","author":"Heersping","year":"2023","unstructured":"139. Heersping H, Aperloo E, Davies M, Dicker D, Kandler K, Rosenstock J, et al. Effects of Semaglutide on Albuminuria and Kidney Function in People with Overweight or Obesity with or Without Type 2 Diabetes: Exploratory Analysis from the STEP 1, 2, and 3 Trials. Diabetes Care. 2023;46(4):801-10. doi: 10.2337\/dc22-1889.","journal-title":"Diabetes Care"},{"issue":"7","key":"key20241203121637_B140","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1038\/s41591-024-03015-5","article-title":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","volume":"30","author":"Colhoun","year":"2024","unstructured":"140. Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058-66. doi: 10.1038\/s41591-024-03015-5.","journal-title":"Nat Med"},{"issue":"2","key":"key20241203121637_B141","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","unstructured":"141. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-21. doi: 10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"issue":"19","key":"key20241203121637_B142","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","unstructured":"142. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-44. doi: 10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"issue":"24","key":"key20241203121637_B143","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","unstructured":"143. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-32. doi: 10.1056\/NEJMoa2307563.","journal-title":"N Engl J Med"},{"issue":"12","key":"key20241203121637_B144","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","volume":"389","author":"Kosiborod","year":"2023","unstructured":"144. Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. NEJM. 2023;389(12):1069-84. doi: 10.1056\/NEJMoa2306963.","journal-title":"NEJM"},{"key":"key20241203121637_B145","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2147\/DDDT.S55587","article-title":"Naltrexone sustained-release\/bupropion sustained-release for the management of obesity: review of the data to date","volume":"8","author":"Caixas","year":"2014","unstructured":"145. Caixas A, Albert L, Capel I, Rigla M. Naltrexone sustained-release\/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014;8:1419-27. doi: 10.2147\/DDDT.S55587.","journal-title":"Drug Des Devel Ther"},{"key":"key20241203121637_B146","year":"2023","unstructured":"146. Cloridrato de naltrexona, cloridrato de bupropiona (Contrave). Rio de Janeiro: Merck S.A.; 2023. Available from: https:\/\/www.merckgroup.com\/br-pt\/bulario\/Contrave_PF_20122021.pdf. Accessed on: Jun 2024.","journal-title":"Cloridrato de naltrexona, cloridrato de bupropiona (Contrave)"},{"issue":"22","key":"key20241203121637_B147","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","article-title":"Association of Pharmacological Treatments for Obesity with Weight Loss and Adverse Events: A Systematic Review and Meta-analysis","volume":"315","author":"Khera","year":"2016","unstructured":"147. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of Pharmacological Treatments for Obesity with Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016;315(22):2424-34. doi: 10.1001\/jama.2016.7602.","journal-title":"JAMA"},{"issue":"9741","key":"key20241203121637_B148","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","unstructured":"148. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. doi: 10.1016\/S0140-6736(10)60888-4.","journal-title":"Lancet"},{"issue":"5","key":"key20241203121637_B149","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","unstructured":"149. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935-43. doi: 10.1002\/oby.20309.","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"key20241203121637_B150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","unstructured":"150. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, et al. Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110-20. doi: 10.1038\/oby.2010.147.","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"key20241203121637_B151","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","unstructured":"151. Hollander P, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12): 4022-9. Erratum in: Diabetes Care. 2014;37(2):587. doi: 10.2337\/dc13-0234.","journal-title":"Diabetes Care"},{"issue":"1","key":"key20241203121637_B152","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/oby.2008.461","article-title":"Rational design of a combination medication for the treatment of obesity","volume":"17","author":"Greenway","year":"2009","unstructured":"152. Greenway FL, Whitehouse MJ, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009;17(1):30-9. doi: 10.1038\/oby.2008.461.","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"key20241203121637_B153","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1210\/jc.2009-1350","article-title":"Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo","volume":"94","author":"Greenway","year":"2009","unstructured":"153. Greenway FL, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009;94(12):4898-906. doi: 10.1210\/jc.2009-1350.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"key20241203121637_B154","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/dom.12095","article-title":"Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity","volume":"15","author":"Smith","year":"2013","unstructured":"154. Smith SR, Fujioka K, Gupta AK, Billes SK, Burns C, Kim D, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab. 2013;15(9):863-6. doi: 10.1111\/dom.12095.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"key20241203121637_B155","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/dom.14284","article-title":"Extended-release naltrexone\/bupropion and liver health: pooled, post hoc analysis from four randomized controlled trials","volume":"23","author":"Bajaj","year":"2021","unstructured":"155. Bajaj HS, Burrows M, Blavignac J, Paron E, Camacho F, Gould E, et al. Extended-release naltrexone\/bupropion and liver health: pooled, post hoc analysis from four randomized controlled trials. Diabetes Obes Metab. 2021;23(3):861-5. doi: 10.1111\/dom.14284.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"key20241203121637_B156","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/osp4.156","article-title":"Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone\/bupropion","volume":"4","author":"Halseth","year":"2018","unstructured":"156. Halseth A, Shan K, Gilder K, Malone M, Acevedo L, Fujioka K. Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone\/bupropion. Obes Sci Pract. 2018;4(2):141-52. doi: 10.1002\/osp4.156.","journal-title":"Obes Sci Pract"},{"issue":"10","key":"key20241203121637_B157","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2016.1558","article-title":"Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients with Cardiovascular Risk Factors: A Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","unstructured":"157. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients with Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. 2016;315(10):990-1004. doi: 10.1001\/jama.2016.1558.","journal-title":"JAMA"},{"key":"key20241203121637_B158","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","unstructured":"158. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi: 10.1016\/j.molmet.2018.09.009.","journal-title":"Mol Metab"},{"issue":"10295","key":"key20241203121637_B159","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0140-6736(21)01390-8","article-title":"Tirzepatide and the new era of twincretins for diabetes","volume":"398","author":"Tan","year":"2021","unstructured":"159. Tan TM, Khoo B. Tirzepatide and the new era of twincretins for diabetes. Lancet. 2021;398(10295):95-7. doi: 10.1016\/S0140-6736(21)01390-8.","journal-title":"Lancet"},{"issue":"1","key":"key20241203121637_B160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7570\/jomes22067","article-title":"Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management","volume":"32","author":"Sinha","year":"2023","unstructured":"160. Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. Obes Metab Syndr. 2023;32(1):25-45. doi: 10.7570\/jomes22067.","journal-title":"Obes Metab Syndr"},{"issue":"3","key":"key20241203121637_B161","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","unstructured":"161. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-16. doi: 10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"issue":"10295","key":"key20241203121637_B162","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","unstructured":"162. Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, Fern\u00e1ndez Land\u00f3 L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-55. doi: 10.1016\/S0140-6736(21)01324-6.","journal-title":"Lancet"},{"issue":"6","key":"key20241203121637_B163","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Fri\u00b4as","year":"2021","unstructured":"163. Fri\u00b4as JP, Davies MJ, Rosenstock J, Pe\u00b4rez Manghi FC, Ferna\u00b4ndez Lando\u00b4 L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-15. doi: 10.1056\/NEJMoa2107519.","journal-title":"N Engl J Med"},{"issue":"10300","key":"key20241203121637_B164","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","unstructured":"164. Ludvik B, Giorgino F, J\u00f3dar E, Frias JP, Land\u00f3 LF, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-98. doi: 10.1016\/S0140-6736(21)01443-4.","journal-title":"Lancet"},{"issue":"10313","key":"key20241203121637_B165","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","unstructured":"165. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-24. doi: 10.1016\/S0140-6736(21)02188-7.","journal-title":"Lancet"},{"issue":"6","key":"key20241203121637_B166","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial","volume":"327","author":"Dahl","year":"2022","unstructured":"166. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534-45. doi: 10.1001\/jama.2022.0078.","journal-title":"JAMA"},{"issue":"10402","key":"key20241203121637_B167","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","unstructured":"167. Garvey WT, Frias JP, Jastreboff AM. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-26. doi: 10.1016\/S0140-6736(23)01200-X.","journal-title":"Lancet"},{"issue":"11","key":"key20241203121637_B168","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","unstructured":"168. Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909-18. doi: 10.1038\/s41591-023-02597-w.","journal-title":"Nat Med"},{"issue":"1","key":"key20241203121637_B169","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial","volume":"331","author":"Aronne","year":"2024","unstructured":"169. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi: 10.1001\/jama.2023.24945.","journal-title":"JAMA"},{"issue":"5","key":"key20241203121637_B170","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/dc22-1710","article-title":"Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with Type 2 Diabetes","volume":"46","author":"Heise","year":"2023","unstructured":"170. Heise T, DeVries H, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with Type 2 Diabetes. Diabetes Care. 2023;46(5):998-1004. doi: 10.2337\/dc22-1710.","journal-title":"Diabetes Care"},{"issue":"12","key":"key20241203121637_B171","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1111\/dom.15269","article-title":"Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial","volume":"25","author":"Hankosky","year":"2023","unstructured":"171. Hankosky E, Wang H, Neff LM. Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial. Diabetes Obes Metab. 2023;25(12):3748-56. doi: 10.1111\/dom.15269.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"key20241203121637_B172","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","unstructured":"172. Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, et al. Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251-61. doi: 10.1007\/s00125-022-05715-4.","journal-title":"Diabetologia"},{"issue":"23","key":"key20241203121637_B173","article-title":"Tirzepatide: A Systematic Update","volume":"23","author":"Forzana","year":"2022","unstructured":"173. Forzana I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G, et al. Tirzepatide: A Systematic Update. Int J Mol Sci. 2022;23(23):14631. doi: 10.3390\/ijms232314631.","journal-title":"Int J Mol Sci"},{"key":"key20241203121637_B174","author":"Lilly","unstructured":"174. Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity. Lilly. [Internet]. Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/tirzepatide-reduced-sleep-apnea-severity-nearly-two-thirds. Accessed on: Jun 2024.","journal-title":"Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity"},{"issue":"6","key":"key20241203121637_B175","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","unstructured":"175. Gastaldelli A, Cusi K, Land\u00f3 LF, Bray R, Brouwers B, Rodr\u00edguez A, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393-406. doi: 10.1016\/S2213-8587(22)00070-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"key20241203121637_B176","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes","volume":"43","author":"Hartman","year":"2020","unstructured":"176. Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, et al. Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes. Diabetes Care. 2020;43(6):1352-5. doi: 10.2337\/dc19-1892.","journal-title":"Diabetes Care"},{"issue":"4","key":"key20241203121637_B177","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","unstructured":"177. Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. doi: 10.1056\/NEJMoa2401943.","journal-title":"N Engl J Med"},{"issue":"12","key":"key20241203121637_B178","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s13300-023-01485-3","article-title":"Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial","volume":"14","author":"Ishii","year":"2023","unstructured":"178. Ishii H, Oura T, Takeuchi M. Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial. Diabetes Ther. 2023;14(12):2173-83. doi: 10.1007\/s13300-023-01485-3.","journal-title":"Diabetes Ther"},{"issue":"11","key":"key20241203121637_B179","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","unstructured":"179. Heerspink HJ, Sattar N, Pavo I, Haupt A, Duffin KL, Yang Z, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11):774-85. doi: 10.1016\/S2213-8587(22)00243-1.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"key20241203121637_B180","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","unstructured":"180. Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591-8. doi: 10.1038\/s41591-022-01707-4.","journal-title":"Nat Med"},{"issue":"6","key":"key20241203121637_B181","first-page":"505","article-title":"Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity","volume":"50","author":"Smith","year":"2001","unstructured":"181. Smith IG, Goulder MA; Sibutramine Clinical Study 1047 Team. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001;50(6):505-12.","journal-title":"J Fam Pract"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T12:17:27Z","timestamp":1733228247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/pharmacologic-treatment-of-obesity-in-adults-and-its-impact-on-comorbidities-2024-update-and-position-statement-of-specialists-from-the-brazilian-association-for-the-study-of-obesity-and-metabolic-sy\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":181,"alternative-id":["10.20945\/2359-4292-2024-0422"],"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2024-0422","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e240422"}}